drugset
drugset / Trial / NCT05696847

A Study of Tirzepatide (LY3298176) in Pediatric Participants With Obesity

NCT05696847 ↗

Phase 1 Completed 28 enrolled Eli Lilly and Company
RandomizedParallel-groupDouble-blindBasic science

Summary

The main purpose of this study is to evaluate the safety and tolerability of tirzepatide (LY3298176) in pediatric participants with obesity. The blood tests will be performed to investigate how the body processes the study drug in these participants. For each participant, the study will last about approximately 13 weeks excluding the screening period.

Timeline

Start
2023-02-07
Primary completion
2025-01-16
Completion
2025-01-16

Drugs

EvaluationDrugModalityDoseRoute
Subject Tirzepatide Peptide 2.5 mg Subcutaneous
Subject Tirzepatide Peptide 5 mg Subcutaneous

Indications

obesity disorder